Skip to main content
KREDKRED
226950KOSDAQ

Olix Pharmaceuticals

117,300
-5,400 (-4.40%)

Price chart

  • MA5
  • MA20
  • MA60

Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.

Market capitalizationKRW 1T

Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.

Overview

Summary

Olix Pharmaceuticals is a company established on February 26, 2010. It is listed on the KOSDAQ market and is headquartered in Seongnam, Gyeonggi-do.

The company develops treatments for difficult diseases using RNA interference platform technology. It focuses on developing new drugs based on its proprietary cp-asiRNA technology and generates revenue by transferring platform and candidate substance technologies to domestic and international pharmaceutical companies.

Business overview as filed

당사는 RNA간섭(RNA interference; RNAi) 플랫폼 기술을 기반으로 기존 치료제가 접근하기 어려운 질환에 대한 치료제를 개발하는 신약개발 기업입니다. RNA간섭기술은 기존 신약개발 플랫폼인 저분자화합물 및 항체치료제를 이은 제3세대 플랫폼 기술로 불리는 올리고 핵산치료제 중, 질병의 원인이 되는 유전자 발현 및 단백질 생성을 효율적으로 억제할 수 있는 현실화된 기술입니다. 당사는 RNA간섭기술 중 siRNA에 대한 원천기술인 "자가전달 비대칭 siRNA(cp-asiRNA)" 기술을 확보하여, 이를 기반으로 난치성 질환에 대한 다양한 신약을 개발하는데 역량을 집중하고 있으며, RNA간섭기술 플랫폼 및 신약 후보물질 관련 기술을 국내외 제약사에 이전하여 수익화하는 사업을 영위하고 있습니다.

당사가 확보한 RNA간섭 플랫폼 기술은 siRNA 치료제의 구성 요소이자 치료제 개발의 기술적 hurdle인 1) siRNA 구조와 2) 표적 단백질에 대한 siRNA의 염기 서열, 3) 효율적인 세포내 전달 기술을 모두 확보하고 있습니다. 당사의 독자적인 RNAi 플랫폼 기술은 1) 염기 서열 변경만으로 모든 유전자 표적이 가능하며 2) 후보물질 선정 기간을 1년이내로 획기적 단축과 3) 비대칭구조를 이용한 오프타겟 효과 및 면역 반응 유발을 최소화 할 수 있는 차별적인 경쟁우위를 갖고 있는 기술입니다. 또한 세포 내 전달 기술을 확보하여 '간 외 전달' 의 경우 소수성 물질을 결합하여 별도의 전달체 없이 전달하고, '간 전달'을 위해 GalNAc과 OliX 독점 개발 링커를 통해 간 세포 내 전달 효율을 높인 바 있습니다. 나아가 현재 두 가지 유전자 표적이 가능한 GalNAc-bi-asiRNA 플랫폼을 함께 연구개발 중에 있습니다.

Company overview

1) 연결대상 종속회사 개황

(1) 연결대상 종속회사 현황(요약)

(2) 연결대상회사의 변동내용

2) 회사의 법적, 사업적 명칭

당사의 명칭은 '올릭스 주식회사'라고 표기합니다. 또한 영문으로는 'OliX Pharmaceuticals, Inc'로 표기합니다.

3) 설립일자 및 존속기간

당사는 2010년 2월 26일 설립되었습니다.

4) 회사의 주소, 전화번호 및 홈페이지

(1) 주소 : 경기도 성남시 수정구 대왕판교로 953, 올릭스(주) R&D Center(2) 홈페이지 : http://www.olixpharma.com(3) 전화번호 : 031-779-8400

5) 중소기업 등 해당 여부

중소기업확인서.jpg 중소기업확인서 벤처기업확인서.jpg 벤처기업확인서

6) 주요사업의 내용 및 신규사업

(1) 회사가 영위하는 목적 사업

당사는 RNA간섭(RNA interference; RNAi) 플랫폼 기술을 기반으로 기존 치료제가 접근하기 어려운 질환에 대한 치료제의 개발 등을 주요 사업으로 영위하고 있으며, 당사의 정관상 목적사업은 다음과 같습니다.

(2) 향후 추진하고자 하는 사업

자세한 사항은 「II. 사업의 내용」을 참고 바랍니다.

7) 계열회사에 관한 사항

당사는 보고서 기준일 현재 독점규제 및 공정거래에 관한 법률 상의 대규모기업집단에 속하여 있지 않습니다.

8) 신용평가에 관한 사항

당사는 보고서 제출일 현재 해당사항이 없습니다.

9)「상법」제290조에 따른 변태설립사항

당사는 보고서 제출일 현재 해당사항이 없습니다.

10) 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항

Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.18), tables and figures omitted.

  • The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
  • The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.

VaR

7.75%
[5.70%, 11.69%] · As of 2026-10-02
VaR by window

The headline's measure for each of the three windows on one scale, the dot being the estimate and the bar its interval. The windows are nested and share their observations, so the three readings are not three independent measurements. The selected window is highlighted.

Daily return distribution

The issue's daily returns over the chosen window counted into equal-width bins. The vertical lines mark the VaR and cVaR above on the loss side. The published VaR sample applies exclusion rules for halts and first sessions that this raw daily series does not, so the bars and the marks can differ slightly at the edges.

Drawdown

Deepest drawdown 56.8% (2026-07-30). How far below its previous peak the issue stood each day over the chosen window, a description of the path already travelled.

If these numbers are unfamiliarThere is a guide that walks through VaR, cVaR and annualized volatility in plain language.Read the guide

Characteristic line

1.09
Beta [0.92, 1.26] · KOSDAQ150 · As of 2026-10-08
Intercept
+0.167%[-0.411%, +0.745%]
R squared
0.37
Observations
252
Trading-time corrected beta
1.04[0.71, 1.36]
252-day rolling beta

A 252-day window rolled one day at a time over the longest daily span of the characteristic line. It shows when the beta against the KOSDAQ150 and the annualized volatility of the issue's excess return rose and fell, and unlike the headline figures above it carries no interval.

252-day rolling annualized volatility

Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.

Financials

2016Separate basis2017Separate basis2018Consolidated basis2019Consolidated basis2020Consolidated basis2021Consolidated basis2022Consolidated basis2023Consolidated basis2024Consolidated basis2025Consolidated basisTTMConsolidated basis
RevenueKRW 100M——3————————
Operating incomeKRW 100M-38-54-82-151-162-254-224-182-309-300-416
Net incomeKRW 100M-37-52-77-144-194-303-219-191-407-157-140
Attributable to ownersKRW 100M———-144-194-297-195-191-407-157-140
Attributable to minoritiesKRW 100M———00-6-24000—
Operating margin%——-2,726.47————————
Net margin%——-2,563.58————————
ROE%———-34.34-42.81-160.44-29.58-38.31-227.79-10.54-5.93
ROA%-24.13-23.86-13.92-31.75-24.67-34.93-16.50-18.58-57.07-8.06-5.12
Debt ratio%20.6415.871.278.1373.27346.59100.37104.28285.7030.1815.43
Current ratio%1,212.451,566.0215,504.391,359.231,538.40129.42164.49489.7251.68660.461,173.74
Quick ratio%1,212.451,495.3315,302.271,345.951,531.63128.49162.83482.5849.83658.601,171.46
Reserve ratio%448.00601.751,565.821,125.28394.63-20.78462.68230.05-75.041,183.591,874.81
EPSKRW-840-1,112-1,369-2,204-1,474-2,171-1,423-1,192-2,203-800-690
PERNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable
BPSKRW———6,4013,3441,3524,8103,1129677,39911,646
PBRx———6.6215.0430.334.234.6819.9218.9813.36
Dividend per shareNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable

Cash flow by activityKRW 100M

Balance sheet compositionKRW 100M

Debt ratio%

The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.

Owners' net margin%

Asset turnoverx

Financial leveragex

ROE%

ROE is the product of the owners' net margin, asset turnover and financial leverage. All three use period-end balances as denominators, and profit and equity are on the owners' basis, so the product matches the ROE in the table.

Financial statements

Balance sheet

2016201720182019202020212022202320242025
1512165564527868671,3271,0287121,954
2630734332673664525528453
1261875494184541946625031851,501

Income statement

2016201720182019202020212022202320242025
Not applicableNot applicable3Not applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable
-38-54-82-151-162-254*-224-182-309-300
-37-52-77-142-205-311*-291-182-411-133
-37-52-77-144-194-303-219-191-407-157
Basic earnings per shareKRW-840-1,112-1,369*-2,204*-1,474-2,171Not applicableNot applicableNot applicable-800
Diluted earnings per shareKRW-840-1,112-1,369*-2,204*-1,474-2,171Not applicableNot applicableNot applicable-800
-37-52-79-144-197-303-169-224-489-171

Cash flow statement

2016201720182019202020212022202320242025
Net incomefrom the income statement-37-52-77-144-194-303-219-191-407-157
Total adjustments to operating cash flowcomputed24-636156112-88-21126-2
-34-48-84-107-38-191-307-212-280-159
-78-58-317126-314155-54834410-1,049
991074232417266560-611851,238
Cash at beginning of periodKRW 100M196728501133434912039
672850113343491203964
Net change in cash and cash equivalentsKRW 100M-130212164230-29471-8125

In the latest fiscal year operations and investing consumed cash raised through financing activities.

A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.

Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.

The newest annual filing shown was received on 2026.03.18.

Audit opinion

Fiscal yearOpinionAuditorFiscal year end
2025적정의견Term 16인덕회계법인2025-12-31
2024적정의견Term 15대주회계법인2025-12-31
2023적정의견Term 14대주회계법인2025-12-31
2022적정Term 13대주회계법인2022-12-31
2021적정Term 12대주회계법인2022-12-31
2020적정Term 11대주회계법인2022-12-31
2019적정Term 10대주회계법인2019-12-31
2018적정Term 9대주회계법인2019-12-31
2017적정Term 8한울회계법인2019-12-31

The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.

Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.

Valuation

Valuation multiplesx

PER and PBR divide each period's closing price by the per-share figure filed for that same period, and a loss period is left blank. The quarterly view is a multiple of quarterly EPS.

Valuation models

Five models priced under one set of assumptions, set beside the current price, with how each has moved by fiscal year.

Assumptions

Risk-free rate10-year treasury yield · 2026-10-084.40%
BetaDaily 5Y0.94
%
%
Cost of equity9.10%
Weighted average cost of capital—
Initial growth0.0%
Effective tax rate0.0%
Base fiscal year2025
Current priceKRW117,300

The risk premium and the terminal growth rate are adjustable assumptions, and the rest follow from the data and the formulas.

ModelModel priceKRWVersus current price
Gordon growth modelNo dividend
Dividend discount model DDMNo dividend
Discounted cash flow FCFFNo cash flow lines
Discounted cash flow FCFENo cash flow lines
Residual income model RIM-5,912-105.0%
The table prices the newest fiscal year's accounts at today's treasury yield and the current price.

Dividend and residual income familyKRW

Discounted cash flow familyKRW

Each fiscal year's figures use that year's accounts and the treasury yield at its period end, with beta held at its current value, and splits or par changes are restated to the current share basis.

How the figures are calculated

Each model's formula is shown in symbols and then with this issue's own numbers substituted, step by step. Changing a value in the assumptions panel changes the numbers here too. Firm-level amounts are in hundred million won and per-share values in won.

Cost of equity

r=rf+β×ERPr = r_f + \beta \times \mathit{ERP}

r = 4.40% + 0.94 × 5.00% = 9.10%

Initial growth

g1=max⁡{ROE×(1−payout), 0},gt=g1+(gT−g1) t−1N−1g_1 = \max\{\mathit{ROE} \times (1 - \text{payout}),\,0\},\qquad g_t = g_1 + (g_T - g_1)\,\frac{t-1}{N-1}

g_1 = max(-10.54% × (1 − 0.00%), 0) = 0.00%

Growth starts at this value in the first year and falls by equal steps each year to reach the terminal rate in the fifth

Residual income model RIM

P0=B0+∑t=1NRIt(1+r)t+RIN(1+gT)(r−gT) (1+r)N,RIt=(ROE−r) Bt−1P_0 = B_0 + \sum_{t=1}^{N} \frac{\mathit{RI}_t}{(1+r)^t} + \frac{\mathit{RI}_N (1+g_T)}{(r - g_T)\,(1+r)^N},\qquad \mathit{RI}_t = (\mathit{ROE} - r)\,B_{t-1}

B_0 = 7,399 KRW, ROE = -10.54%, payout ratio = 0.00%, r = 9.10%, g_T = 2.00%

YearOpening book valueEarningsEquity chargeResidual incomeDiscount factorPresent value
17,399-780673-1,4530.9166-1,332
26,619-698602-1,3000.8402-1,092
35,921-624539-1,1630.7702-895
45,297-558482-1,0400.7059-734
54,739-499431-9300.6471-602
Terminal value-13,3760.6471-8,656

P_0 = 7,399 + -4,655 + -8,656 = -5,912 KRW

The cost of equity is the risk-free rate plus beta times the equity risk premium. Initial growth is the newest fiscal year's return on equity times its retention ratio, floored at zero, and falls by equal steps from that value in the first year to the terminal rate in the fifth. Only the Gordon model grows at the terminal rate from the start. Discounted cash flow starts from operating cash flow less capital expenditure, where FCFF adds after-tax interest paid and discounts at the weighted average cost of capital, and FCFE adds net borrowing and discounts at the cost of equity. The residual income model adds to book value per share the present value of earnings above the equity charge.

Other issues on the same market

Neighbours in the market capitalisation order.

See the full KOSDAQ list